These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 26679899

  • 1. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
    Cheng L, Davidson DD, Wang M, Lopez-Beltran A, Montironi R, Wang L, Tan PH, MacLennan GT, Williamson SR, Zhang S.
    Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
    [Abstract] [Full Text] [Related]

  • 2. [Significance of TERT promoter mutation in differential diagnosis of non-invasive inverted urothelial lesions of bladder].
    Zhang YH, Xie JJ, Wang JG, Wang Y, Zhan XH, Gao J, He HY.
    Zhonghua Bing Li Xue Za Zhi; 2023 Dec 08; 52(12):1216-1222. PubMed ID: 38058037
    [Abstract] [Full Text] [Related]

  • 3. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B, Zhuge J, Ojaimi C, Ye F, Cai D, Zhang D, Fallon JT, Zhong M.
    Ann Diagn Pathol; 2016 Apr 08; 21():7-11. PubMed ID: 27040924
    [Abstract] [Full Text] [Related]

  • 4. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
    Wang CC, Huang CY, Jhuang YL, Chen CC, Jeng YM.
    Histopathology; 2018 Apr 08; 72(5):795-803. PubMed ID: 29193225
    [Abstract] [Full Text] [Related]

  • 5. Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation.
    Zhong M, Tian W, Zhuge J, Zheng X, Huang T, Cai D, Zhang D, Yang XJ, Argani P, Fallon JT, Epstein JI.
    Am J Surg Pathol; 2015 Jan 08; 39(1):127-31. PubMed ID: 25118812
    [Abstract] [Full Text] [Related]

  • 6. Telomere shortening distinguishes inverted urothelial neoplasms.
    Williamson SR, Zhang S, Lopez-Beltran A, Montironi R, Wang M, Cheng L.
    Histopathology; 2013 Mar 08; 62(4):595-601. PubMed ID: 23379729
    [Abstract] [Full Text] [Related]

  • 7. Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications.
    Cheng L, Lopez-Beltran A, Wang M, Montironi R, Kaimakliotis HZ, Zhang S.
    Mod Pathol; 2021 Jul 08; 34(7):1384-1391. PubMed ID: 33674765
    [Abstract] [Full Text] [Related]

  • 8. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
    Priemer DS, Wang M, Zhang S, Lopez-Beltran A, Kouba E, Montironi R, Davidson DD, MacLennan GT, Wang L, Osunkoya AO, Deng Y, Emerson RE, Cheng L.
    Eur Urol Focus; 2018 Dec 08; 4(6):880-888. PubMed ID: 28753872
    [Abstract] [Full Text] [Related]

  • 9. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
    Vail E, Zheng X, Zhou M, Yang X, Fallon JT, Epstein JI, Zhong M.
    Ann Diagn Pathol; 2015 Oct 08; 19(5):301-5. PubMed ID: 26239299
    [Abstract] [Full Text] [Related]

  • 10. Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.
    Isharwal S, Hu W, Sarungbam J, Chen YB, Gopalan A, Fine SW, Tickoo SK, Sirintrapun SJ, Jadallah S, Loo FL, Pietzak EJ, Cha EK, Bochner BH, Berger MF, Iyer G, Solit DB, Reuter VE, Al-Ahmadie H.
    J Pathol; 2019 Jul 08; 248(3):260-265. PubMed ID: 30838648
    [Abstract] [Full Text] [Related]

  • 11. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
    Xiao L, Wang CF, Zhu XZ, Yin YL, Chen Y, Lu C, Yu B.
    Zhonghua Bing Li Xue Za Zhi; 2011 May 08; 40(5):319-23. PubMed ID: 21756826
    [Abstract] [Full Text] [Related]

  • 12. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.
    Hayashi Y, Fujita K, Nojima S, Tomiyama E, Matsushita M, Koh Y, Nakano K, Wang C, Ishizuya Y, Kato T, Hatano K, Kawashima A, Ujike T, Uemura M, Imamura R, Morii E, Nonomura N.
    Mol Oncol; 2020 Oct 08; 14(10):2375-2383. PubMed ID: 32533903
    [Abstract] [Full Text] [Related]

  • 13. TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers.
    Weyerer V, Eckstein M, Strissel PL, Wullweber A, Lange F, Tögel L, Geppert CI, Sikic D, Taubert H, Wach S, Wullich B, Hartmann A, Stoehr R, Giedl J.
    Genes (Basel); 2021 Feb 05; 12(2):. PubMed ID: 33562516
    [Abstract] [Full Text] [Related]

  • 14. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
    Thiem S, Herold T, Krafft U, Bremmer F, Tolkach Y, Szász AM, Kriegsmann J, Gaisa NT, Niedworok C, Szarvas T, Reis H.
    Pathol Int; 2017 Dec 05; 67(12):597-601. PubMed ID: 29047227
    [Abstract] [Full Text] [Related]

  • 15. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
    Nguyen D, Taheri D, Springer S, Cowan M, Guner G, Mendoza Rodriguez MA, Wang Y, Kinde I, VandenBussche CJ, Olson MT, Ricardo BF, Cunha I, Fujita K, Ertoy D, Kinzler KW, Bivalacqua TJ, Papadopoulos N, Vogelstein B, Netto GJ.
    Virchows Arch; 2016 Oct 05; 469(4):427-34. PubMed ID: 27520411
    [Abstract] [Full Text] [Related]

  • 16. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.
    Cheng L, Zhang S, Wang M, Lopez-Beltran A.
    Hum Pathol; 2023 Mar 05; 133():56-75. PubMed ID: 35700749
    [Abstract] [Full Text] [Related]

  • 17. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y, Beukers W, Sagrera A, Flández M, Marqués M, Márquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX.
    Eur Urol; 2014 Feb 05; 65(2):360-6. PubMed ID: 24018021
    [Abstract] [Full Text] [Related]

  • 18. Inverted papilloma of the bladder: a review and an analysis of the recent literature of 365 patients.
    Picozzi S, Casellato S, Bozzini G, Ratti D, Macchi A, Rubino B, Pace G, Carmignani L.
    Urol Oncol; 2013 Nov 05; 31(8):1584-90. PubMed ID: 22520573
    [Abstract] [Full Text] [Related]

  • 19. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
    Palsgrove DN, Taheri D, Springer SU, Cowan M, Guner G, Mendoza Rodriguez MA, Rodriguez Pena MDC, Wang Y, Kinde I, Ricardo BFP, Cunha I, Fujita K, Ertoy D, Kinzler KW, Bivalacqua TJ, Papadopoulos N, Vogelstein B, Netto GJ.
    Hum Pathol; 2019 Mar 05; 85():1-9. PubMed ID: 30447301
    [Abstract] [Full Text] [Related]

  • 20. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.
    Günes C, Wezel F, Southgate J, Bolenz C.
    Nat Rev Urol; 2018 Jun 05; 15(6):386-393. PubMed ID: 29599449
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.